{
    "ticker": "BLCO",
    "name": "Biosplice Therapeutics, Inc.",
    "description": "Biosplice Therapeutics, Inc. is a biopharmaceutical company focused on developing innovative therapies for patients with degenerative diseases. Founded in 2015, the company is dedicated to leveraging its proprietary technology platform to create novel treatments that address unmet medical needs in areas such as musculoskeletal disorders and cancer. Biosplice's lead product candidate, a gene therapy aimed at treating osteoarthritis, utilizes a unique approach to deliver therapeutic agents directly to the affected joint, potentially reducing pain and improving mobility for patients. The company\u2019s mission is to enhance the quality of life for patients by providing effective, safe, and accessible therapeutic options. With a robust pipeline of candidates in various stages of development, Biosplice is committed to advancing its research through strategic partnerships and collaborations with leading academic institutions and healthcare organizations. The company operates with a strong emphasis on scientific integrity and patient-centric values, striving to bring transformative therapies to market that can significantly impact patient outcomes.",
    "industry": [
        "Biotechnology",
        "Pharmaceuticals"
    ],
    "headquarters": "San Diego, California, USA",
    "founded": "2015",
    "website": "https://www.biosplicetherapeutics.com",
    "ceo": "John Doe",
    "social_media": {
        "twitter": "https://twitter.com/Biosplice",
        "linkedin": "https://www.linkedin.com/company/biosplice-therapeutics/"
    },
    "investor_relations": "https://ir.biosplicetherapeutics.com",
    "key_executives": [
        {
            "name": "John Doe",
            "position": "CEO"
        },
        {
            "name": "Jane Smith",
            "position": "CFO"
        }
    ],
    "product_categories": [
        {
            "category": "Therapeutics",
            "products": [
                "Gene Therapy for Osteoarthritis"
            ]
        }
    ],
    "seo": {
        "meta_title": "Biosplice Therapeutics, Inc. | Innovative Biopharmaceutical Solutions",
        "meta_description": "Explore Biosplice Therapeutics, Inc., a biopharmaceutical company dedicated to developing innovative therapies for degenerative diseases. Learn about our mission and product pipeline.",
        "keywords": [
            "Biosplice",
            "Biopharmaceuticals",
            "Gene Therapy",
            "Osteoarthritis"
        ]
    },
    "faq": [
        {
            "question": "What does Biosplice Therapeutics focus on?",
            "answer": "Biosplice Therapeutics focuses on developing innovative therapies for patients with degenerative diseases."
        },
        {
            "question": "Where is Biosplice headquartered?",
            "answer": "Biosplice is headquartered in San Diego, California, USA."
        },
        {
            "question": "What is Biosplice's lead product candidate?",
            "answer": "Biosplice's lead product candidate is a gene therapy aimed at treating osteoarthritis."
        },
        {
            "question": "When was Biosplice founded?",
            "answer": "Biosplice was founded in 2015."
        }
    ],
    "competitors": [
        "AMGN",
        "REGN",
        "NVS"
    ],
    "related_stocks": [
        "GILD",
        "VRTX",
        "BIIB",
        "ABBV"
    ]
}